GlobeNewswire

SolarWinds Cloud Portfolio Enhancements Strengthen Capabilities for Both Infrastructure and Application Monitoring

Dela

Tighter integration and new features empower users to monitor more hosts and more applications, more affordably

AUSTIN, Texas, June  07, 2018  (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced significant enhancements across its SolarWinds Cloud® portfolio of SaaS-based products, including updates to AppOptics(TM), Pingdom®, Papertrail(TM) and Loggly® offerings. These SolarWinds Cloud enhancements have been designed to deepen visibility across both cloud infrastructure and applications to simplify full-stack monitoring for DevOps and IT Ops professionals and enable a more integrated user experience for customers using more than one product.

New Features and Capabilities for AppOptics, Pingdom, Papertrail and Loggly
Specific enhancements that broaden infrastructure and application monitoring support, and enhance simplicity include:

  • AppOptics - Now offers a unified view to quickly identify outliers and usage patterns through new host map and host list view capabilities. Support for seven programming languages, now including Ruby, Go and Node.js®, enables deeper visibility into infrastructure and applications. The AppOptics integration with Papertrail and Loggly makes logs available to provide contextual information for troubleshooting.
  • Pingdom - Now provides up to 13 months of data to deepen digital experience monitoring. In addition, users can now generate shareable online reports to effectively communicate across teams. 
  • Papertrail - Adds a new event viewer, new velocity graphs and dashboard improvements to accelerate troubleshooting.
  • Loggly - Now offers preconfigured dashboards based on log types to simplify monitoring across complex environments. 

"The power of Papertrail is in its simplicity", said Dave North, director of DevOps at Signiant, a US-based media and entertainment company. "The new features build on the product's usability and add real value. For example, being able to favourite groups on the dashboard saves me time. The new velocity graphs are especially valuable as they let us visualise the error rate and quickly determine whether we have a small or large problem."

In addition to these new features, tighter integration within the portfolio can give users the ability to cross-launch among SolarWinds Cloud products. This means that DevOps professionals can now easily move from a dashboard that highlights load time issues on a web page, for example, into a detailed log view to troubleshoot an application infrastructure issue.

"It is too hard and expensive for DevOps and IT Ops professionals to comprehensively monitor the performance of modern applications in their environment", said Christoph Pfister, executive vice president of products, SolarWinds. "The release today extends our comprehensive monitoring capabilities across infrastructure and applications. Using these powerful, affordable products, our customers will see the full picture of traces, metrics, logs and the digital experience, improving the responsiveness of their applications and making their lives much easier."

The SolarWinds Cloud enhancements are the latest milestones in the company's drive to deliver a set of comprehensive, simple and affordable full-stack monitoring solutions. SolarWinds' goal is to enable a single view of infrastructure, applications and digital experience, which will help customers solve their most complex performance and reliability problems quickly, simply and affordably.

Pricing and Availability
The enhanced SolarWinds Cloud offerings are available immediately. Pricing starts at USD 7.50 per month for AppOptics, USD 9.95 per month for Pingdom, USD 7.00 per month for Papertrail and USD 99.00 per month for Loggly.

*Prices as of 4 June 2018 in US dollars. Pricing may vary based upon the jurisdiction and applicable currency. Please contact a local SolarWinds sales representative to find pricing specific to your jurisdiction.

Additional Resources

Connect with SolarWinds

About SolarWinds
SolarWinds provides powerful and affordable IT management software to customers worldwide, from Fortune 500® enterprises to small businesses, managed service providers (MSPs), government agencies and educational institutions. We are committed to focusing exclusively on IT, MSP and DevOps professionals, and strive to eliminate the complexity that our customers have been forced to accept from traditional enterprise software vendors. Regardless of where the IT asset or user sits, SolarWinds delivers products that are easy to find, buy, use, maintain and scale while providing the power to address key areas of the infrastructure from on-premises to the cloud. This focus and commitment to excellence in end-to-end hybrid IT performance management has established SolarWinds as the worldwide leader in both network management software and MSP solutions, and is driving similar growth across the full spectrum of IT management software. Our solutions are rooted in our deep connection to our user base, which interacts in our THWACK online community to solve problems, share technology and best practices, and directly participate in our product development process. Learn more today at www.solarwinds.com.

The SolarWinds, SolarWinds & Design, Orion, and THWACK trademarks are the exclusive property of SolarWinds Worldwide, LLC or its affiliates, are registered with the US Patent and Trademark Office, and may be registered or pending registration in other countries. All other SolarWinds trademarks, service marks and logos may be common law marks or are registered or pending registration. All other trademarks mentioned herein are used for identification purposes only and are trademarks of (and may be registered trademarks of) their respective companies.

© 2018 SolarWinds Worldwide, LLC. All rights reserved.

MEDIA CONTACTS:  
Nicole Fachet  Jenne Barbour
Text100    SolarWinds
 Phone number: +1 212 871 3950  Phone number: +1 512 498 6804
NicoleF@text100.com pr@solarwinds.com

Images accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/daeb7fcf-3ddf-41c0-97be-238d3044bec0 http://www.globenewswire.com/NewsRoom/AttachmentNg/ee3d687f-4511-48a0-9fd7-3171e56435b6 http://www.globenewswire.com/NewsRoom/AttachmentNg/05156838-17c9-4122-abc3-7bec504e6929 http://www.globenewswire.com/NewsRoom/AttachmentNg/ddce2d73-50d9-4f17-be8d-21ff187c77d5 http://www.globenewswire.com/NewsRoom/AttachmentNg/df7c4694-e876-4a09-b5b0-f24d3d015a37




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SolarWinds Worldwide, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum